Researchers have discovered that anti-PD-1/PD-L1 therapies are highly effective in patients with desmoplastic melanoma, challenging previous assumptions.
In this editorial from Future Oncology, discover how oncolytic viruses may be utilized to target and destroy tumor cells in a currently underexplored immunotheraputic approach.
Researchers have demonstrated that neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer (TNBC) to immune checkpoint therapy.
Would you like to discover exclusive content from the hottest topics in oncology? Editor, Jade Parker, highlights Oncology Centrals top content in this report.
Researchers have presented the association between tumor response and health-related quality of life in patients with metastatic Merkel cell carcinoma treated with avelumab.
Recent results from Roche’s Phase III IMpower 150 lung cancer study have demonstrated that atezolizumab, bevacizumab, chemotherapy combination doubles 12-month PFS.
Researchers at the University of California (CA, USA) have discovered a neoantigen in a rare childhood brain tumor that binds strongly to T cells.
Patients with cancerous forms of gestational trophoblastic disease went into remission after treatment with pembrolizumab.
In this interview with James Gulley find out about Phase I clinical trial for M7824 (a bifunctional fusion protein immunotherapy that targets both PD-L1 and TGF-beta), which has demonstrated preliminary effectiveness in patients with advanced solid tumors.
This review describes trials evaluating the monoclonal antibody pembrolizumab (an immunotherapy that blocks the interaction between PD-L1/PD-L2) as first-line therapy for advanced non-small-cell lung cancer.